title: CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO.
abstract: To investigate the effects of anemia correction with recombinant human erythropoietin (rhEPO) on both cerebral blood flow and oxygen metabolism in hemodialysis (HD) patients, the regional cerebral blood flow (rCBF), oxygen extraction (rOEF), and metabolic rate for oxygen (rCMRO2) were measured by positron emission tomography in five HD patients, and the data were compared with eight nondemented controls who had neither anemia nor uremia. In the HD patients, 1,500 U of rhEPO were administered intravenously three times a week to achieve a 10% increase in hematocrit (Hct) as an absolute value. Before rhEPO administration, the hemispheric rCMRO2 in HD patients was 1.48 +/- 0.09 (SE) ml.min-1.100 ml-1, which was significantly lower than that of 2.18 +/- 0.10 in the controls (P less than 0.01). In contrast, both rCBF and rOEF were significantly greater in the HD patients than the control, being 40 +/- 3 vs. 32 +/- 3 ml.min-1.100 ml-1 for rCBF (P less than 0.02) and 49 +/- 1 vs. 38 +/- 1% for rOEF (P less than 0.001). After treatment with rhEPO, Hct rose significantly from 21 +/- 1 to 31 +/- 1% in HD patients (P less than 0.001). There were significant reductions in both the hemispheric rCBF to 32 +/- 1 ml.min-1.100 ml-1 (P less than 0.01) and rOEF to 42 +/- 1% (P less than 0.01). However, the hemispheric rCMRO2 remained low at 1.58 +/- 0.06 ml.min-1.100 ml-1 even after rhEPO treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine II, Faculty of Medicine, Kyushu University, Fukuoka City, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hirakata
authors.forename: H
authors.initials: H
authors.lastname: Yao
authors.forename: S
authors.initials: S
authors.lastname: Osato
authors.forename: S
authors.initials: S
authors.lastname: Ibayashi
authors.forename: K
authors.initials: K
authors.lastname: Onoyama
authors.forename: M
authors.initials: M
authors.lastname: Otsuka
authors.forename: Y
authors.initials: Y
authors.lastname: Ichiya
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwabara
authors.forename: Y
authors.initials: Y
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Fujishima
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001921:Brain / Q000378:metabolism*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014055:Tomography, Emission-Computed
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin